NCT04462263

Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects

An Open-label, Single Centre, Single Oral Dose Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Nxera Pharma UK Limited · Industry
• Sex: Male
• Age: 23 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A Study in Healthy Volunteers to Investigate How a New Drug for the Treatment of Parkinson's Disease, Dystonia and Amyotrophic Lateral Sclerosis Binds to Receptor Sites in the Brain.

Detailed description

This is an open-label, single dose, adaptive study of orally adminstered HTL0014242 in up to 10 healthy male subjects. The primary objective is to investigate the pharmacokinetic-receptor occupancy relationship of single oral doses of HTL0014242 in healthy subjects. The secondary objectives are to assess the plasma pharmacokinetics (PK), safety and tolerability of single oral doses of HTL0014242 in healthy subjects.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	HTL0014242	Solid suspension capsule

Timeline

• Start date: 2020-06-29
• Primary completion: 2021-06-23
• Completion: 2021-06-23
• First posted: 2020-07-08
• Last updated: 2021-07-07

Locations

1 site across 1 country: United Kingdom